A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

References

• Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002; 249:609–15.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh P, Guillett P, Meininger V, . Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996; 347:1425–31.
   PubMed Web of Science ®Google Scholar
• Aoki M, Lin CL, Rothstein JD, Geller BA, Hosler BA, Munsat TL, . Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. Ann Neurol. 1998; 43:645–53.
   PubMed Web of Science ®Google Scholar
• Hirata A, Nakamura R, Kwak S, Nagata N, Kamakura K. AMPA receptor-mediated slow neuronal death in the rat spinal cord induced by long-term blockade of glutamate transporters with THA. Brain Res. 1997; 771:37–44.
   PubMed Web of Science ®Google Scholar
• Legay V, Deleage C, Beaulieux F, Giraudon P, Aymard M, Lina B. Impaired glutamate uptake and EAAT2 down-regulation in an enterovirus chronically infected human glial cell line. Eur J Neurosci. 2003; 17:1820–8.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009; 65(Suppl 1):S3–9.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, . Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005; 433:73–7.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995; 38:73–84.
   PubMed Web of Science ®Google Scholar
• Maragakis NJ, Dykes-Hoberg M, Rothstein JD. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol. 2004; 55:469–77.
   PubMed Web of Science ®Google Scholar
• van den Bosch L, Robberecht W. Cross-talk between astrocytes and motor neurons: what is the message?. Exp Neurol. 2008; 211:1–6.
   PubMed Web of Science ®Google Scholar
• Canton T, Bohme GA, Boireau A, Bordier F, Mignani S, Jimonet P, . RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2001; 299:314–22.
   PubMed Web of Science ®Google Scholar
• van Damme P, Leyssen M, Callewaert G, Robberecht W, van den Bosch L. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2003; 343:81–4.
   PubMed Web of Science ®Google Scholar
• Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001; 2:806–19.
   PubMed Web of Science ®Google Scholar
• Jewell H, Lucas R, Schaefer H, Mant T. LY300164: initial experience in healthy subjects. Clin Pharmacol Ther. 1998; 63:188.
   Google Scholar
• Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, . A cross-over, add-on trial of talampanel in patients with refractory partial seizures. Neurology. 2002; 58:1680–2.
   PubMed Web of Science ®Google Scholar
• Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JW, . Talampanel, a new anti-epileptic drug: single- and multiple-dose pharmacokinetics and initial one-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003; 44:46–53.
   PubMed Web of Science ®Google Scholar
• van den Bosch L, van den Berghe W, Klaassen H, van Houtte E, Robberecht W. Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci. 2000; 180:29–34.
   PubMed Web of Science ®Google Scholar
• Greene IP, Lee EY, Prow N, Ngwang B, Griffin DE. Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection. Proc Natl Acad Sci U S A. 2008; 105:3575–80.
   PubMed Web of Science ®Google Scholar
• Denes L, Szilagyi G, Gal A, Nagy Z. Talampanel, a non-competitive AMPA antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia. Brain Res Bull. 2006; 70:260–2.
   PubMed Web of Science ®Google Scholar
• Andres P, Hedlund W, Finison L, Conlon T, Felmus M, Munsat T. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurol. 1986; 36:937–41.
   PubMed Web of Science ®Google Scholar
• Andres PL, Finison L, Thibodeau LM, Munsat TL. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurol. 1988; 38:405–8.
   PubMed Web of Science ®Google Scholar
• Cedarbaum J. The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS). Archives of Neurology. 1996; 53:141–7.
   PubMedGoogle Scholar
• Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2009; July 26:1–3.[Epub ahead of print].
   Google Scholar
• Bryson HM, Fulton B, Benfield P. Riluzole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs. 1996; 52:549–63.
   PubMed Web of Science ®Google Scholar
• van Damme P, van den Bosch L, van Houtte E, Callewaert G, Robberecht W. GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. J Neurophysiol. 2002; 88:1279–87.
   PubMed Web of Science ®Google Scholar
• van den Berghe W, Robberecht W, Brorson JR. AMPA receptor calcium permeability, GluR2 expression, and selective motor neuron vulnerability. J Neurosci. 2000; 20:123–32.
   Google Scholar
• Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JW, . Talampanel, a new anti-epileptic drug: single- and multiple-dose pharmacokinetics and initial one-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003; 44:46–53.
   PubMed Web of Science ®Google Scholar